Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3055082 | 0.86 | LMNA (0.41) | LMNAALDH1A1HPGDUSP2SMN1; SMN2 | |
| SCHEMBL708587 | 0.86 | ALDH1A1 (0.42) | LMNAALDH1A1HPGDUSP2SMN1; SMN2 | |
| SCHEMBL7592790 | 0.85 | LMNA (0.39) | LMNAALDH1A1HPGDUSP2SMN1; SMN2 | |
| SCHEMBL9196383 | 0.84 | LMNA (0.38) | LMNAALDH1A1HPGDUSP2SMN1; SMN2 | |
| SCHEMBL9352669 | 0.82 | LMNA (0.42) | LMNAALDH1A1HPGDUSP2SMN1; SMN2 | |
| SCHEMBL9009307 | 0.81 | LMNA (0.43) | LMNAALDH1A1HPGDUSP2SMN1; SMN2 | |
| SCHEMBL8906827 | 0.81 | ALDH1A1 (0.38) | LMNAALDH1A1HPGDUSP2SMN1; SMN2 | |
| SCHEMBL8741593 | 0.81 | LMNA (0.49) | LMNASMN1; SMN2 | |
| SCHEMBL8741514 | 0.81 | LMNA (0.40) | LMNA | |
| SCHEMBL9188694 | 0.80 | LMNA (0.40) | LMNAALDH1A1HPGDUSP2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2200656-B1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2012-12-05 | — | — | EP | disclosed |
| EP-2200656-B1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2012-12-05 | — | — | EP | disclosed |
| US-8323619-B2 | Contrast agents | GE HEALTHCARE AS (NO) | 2012-12-04 | — | — | US | disclosed |
| US-8323619-B2 | Contrast agents | GE HEALTHCARE AS (NO) | 2012-12-04 | — | — | US | disclosed |
| US-8323619-B2 | Contrast agents | GE HEALTHCARE AS (NO) | 2012-12-04 | — | — | US | disclosed |
| US-8202511-B2 | Contrast agents | GE HEALTHCARE AS (NO) | 2012-06-19 | — | — | US | disclosed |
| US-8202511-B2 | Contrast agents | GE HEALTHCARE AS (NO) | 2012-06-19 | — | — | US | disclosed |
| US-8202511-B2 | Contrast agents | GE HEALTHCARE AS (NO) | 2012-06-19 | — | — | US | disclosed |
| US-20100303734-A1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2010-12-02 | — | — | US | disclosed |
| US-20100303734-A1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2010-12-02 | — | — | US | disclosed |
| US-20100221189-A1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2010-09-02 | — | — | US | disclosed |
| US-20100221189-A1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2010-09-02 | — | — | US | disclosed |
| EP-2205553-A1 | CONTRAST AGENTS | GE Healthcare AS (NO) | 2010-07-14 | — | — | EP | disclosed |
| EP-2200656-A1 | CONTRAST AGENTS | GE Healthcare AS (NO) | 2010-06-30 | — | — | EP | disclosed |
| WO-2009071605-A1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2009-06-11 | — | — | WO | disclosed |
| WO-2009071605-A1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2009-06-11 | — | — | WO | disclosed |
| WO-2009060021-A1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2009-05-14 | — | — | WO | disclosed |
| WO-2009060021-A1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2009-05-14 | — | — | WO | disclosed |
| WO-2009047319-A1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2009-04-16 | — | — | WO | disclosed |
| WO-2009047319-A1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2009-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100221189-A1 | CONTRAST AGENTS | NR1I3, NR1I2, NR1D2 | LMNA 2753/4885ALDH1A1 1588/4885HPGD 2592/4885 |
| US-20100303734-A1 | CONTRAST AGENTS | C1R, CNKSR1, C5 | LMNA 2025/4885ALDH1A1 2186/4885HPGD 1528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.